Mary Wilson
Well-known member
Posted October 26, 2023.
doi: https://doi.org/10.1101/2023.10.24.23297114
Michael J. Peluso1*†, Zoe N. Swank234†, Sarah A. Goldberg5†, Scott Lu5, Thomas Dalhuisen5, Ella Borberg234, Yasmeen Senussi234, Michael A. Luna1, Celina Chang Song1, Alexus Clark1, Andhy Zamora1, Megan Lew1, Badri Viswanathan5, Beatrice Huang1, Khamal Anglin5, Rebecca Hoh1,Priscila Y. Hsue6, Matthew S. Durstenfeld6, Matthew A. Spinelli1, David V. Glidden5, Timothy J. Henrich7, J. Daniel Kelly5, Steven G. Deeks1, David R. Walt234‡ and Jeffrey N. Martin5‡
ABSTRACT
BACKGROUND
Although RNA viruses like SARS-CoV-2 are generally thought to be transient, the persistence of viral components beyond the acute phase can be driven by a variety of virologic and immunologic factors. Recent studies have suggested that SARS-CoV-2 antigens may persist following COVID-19 but were limited by a lack of comparison to a large number of true negative control samples.
METHODS
Using single molecule array (Simoa) assays for SARS-CoV-2 spike, S1, and nucleocapsid antigen in plasma from 171 pandemic-era individuals in the post-acute phase of SARS-CoV-2 infection and 250 pre-pandemic control samples, we compared prevalence of antigen detection. We used logistic regression models and prevalence ratios (PRs) to assess the relationship between demographic and disease factors and antigen persistence.
RESULTS
Compared to the proportion of antigen positivity in the pre-pandemic controls (2%), detection of any SARS-CoV-2 antigen was more frequent across all post-acute COVID-19 time bins (3-6 months: 12.6%, p<0.001; 6-10 months, 10.7%, p=0.0002; 10-14 months, 7.5%, p=0.017). These differences were driven by spike protein for up to 14 months and nucleocapsid in the first 6 months after infection. The co-occurrence of multiple antigens at a single timepoint was uncommon. Hospitalization for acute COVID-19 (versus not hospitalized) and worse self-reported health during acute COVID-19 among those not hospitalized (versus more benign illness) were associated with higher prevalence of post-acute antigen detection (PR 1.86, p=0.03; PR 3.5, p=0.07, respectively) in the pandemic era.
CONCLUSIONS
Our findings provide strong evidence that SARS-CoV-2 antigens can persist beyond the period of acute illness. The observation that more than 10% of plasma samples for over a year following initial SARS-CoV-2 infection contain detectable viral antigen, which are potentially immunogenic, has significant implications given the sheer number of people infected with SARS-CoV-2 to date. More work will be needed to determine whether these antigens have a causal role in post-acute sequelae of SARS-CoV-2 infection (PASC).
https://www.medrxiv.org/content/10.1101/2023.10.24.23297114v2.full-text
doi: https://doi.org/10.1101/2023.10.24.23297114
Michael J. Peluso1*†, Zoe N. Swank234†, Sarah A. Goldberg5†, Scott Lu5, Thomas Dalhuisen5, Ella Borberg234, Yasmeen Senussi234, Michael A. Luna1, Celina Chang Song1, Alexus Clark1, Andhy Zamora1, Megan Lew1, Badri Viswanathan5, Beatrice Huang1, Khamal Anglin5, Rebecca Hoh1,Priscila Y. Hsue6, Matthew S. Durstenfeld6, Matthew A. Spinelli1, David V. Glidden5, Timothy J. Henrich7, J. Daniel Kelly5, Steven G. Deeks1, David R. Walt234‡ and Jeffrey N. Martin5‡
ABSTRACT
BACKGROUND
Although RNA viruses like SARS-CoV-2 are generally thought to be transient, the persistence of viral components beyond the acute phase can be driven by a variety of virologic and immunologic factors. Recent studies have suggested that SARS-CoV-2 antigens may persist following COVID-19 but were limited by a lack of comparison to a large number of true negative control samples.
METHODS
Using single molecule array (Simoa) assays for SARS-CoV-2 spike, S1, and nucleocapsid antigen in plasma from 171 pandemic-era individuals in the post-acute phase of SARS-CoV-2 infection and 250 pre-pandemic control samples, we compared prevalence of antigen detection. We used logistic regression models and prevalence ratios (PRs) to assess the relationship between demographic and disease factors and antigen persistence.
RESULTS
Compared to the proportion of antigen positivity in the pre-pandemic controls (2%), detection of any SARS-CoV-2 antigen was more frequent across all post-acute COVID-19 time bins (3-6 months: 12.6%, p<0.001; 6-10 months, 10.7%, p=0.0002; 10-14 months, 7.5%, p=0.017). These differences were driven by spike protein for up to 14 months and nucleocapsid in the first 6 months after infection. The co-occurrence of multiple antigens at a single timepoint was uncommon. Hospitalization for acute COVID-19 (versus not hospitalized) and worse self-reported health during acute COVID-19 among those not hospitalized (versus more benign illness) were associated with higher prevalence of post-acute antigen detection (PR 1.86, p=0.03; PR 3.5, p=0.07, respectively) in the pandemic era.
CONCLUSIONS
Our findings provide strong evidence that SARS-CoV-2 antigens can persist beyond the period of acute illness. The observation that more than 10% of plasma samples for over a year following initial SARS-CoV-2 infection contain detectable viral antigen, which are potentially immunogenic, has significant implications given the sheer number of people infected with SARS-CoV-2 to date. More work will be needed to determine whether these antigens have a causal role in post-acute sequelae of SARS-CoV-2 infection (PASC).
https://www.medrxiv.org/content/10.1101/2023.10.24.23297114v2.full-text